{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009885","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.351784+00:00","generated_at":"2026-05-16T10:56:10.991217+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028","bullets":["Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).","Offering priced at 30% premium to Jan 9, 2026 closing; investors include BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund.","Pro forma cash, cash equivalents and marketable securities of $208.9M (unaudited) as of Jan 13, 2026; cash runway extended into first half of 2028.","FHD-909 (SMARCA2 inhibitor) Phase 1 dose-escalation trial on track; enrollment in NSCLC patients progressing as planned.","Selective CBP degrader on track to be IND-ready in 2026; selective EP300 degrader expected to enter IND-enabling studies in 2026; ARID1B degrader advancing to in vivo PoC in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009885","json":"https://secwatch.observer/filing/0001193125-26-009885.json","markdown":"https://secwatch.observer/filing/0001193125-26-009885.md","text":"https://secwatch.observer/filing/0001193125-26-009885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000119312526009885/0001193125-26-009885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000119312526009885/d31462d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:56:10.991217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}